ANGELO GUIDO C.
- Country
- Italy
- Department
- SC Pneumologia
Research Overview
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Idiopathic Pulmonary Fibrosis
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Progressive Pulmonary Fibrosis
- A Phase IIb Randomized Study to Evaluate the Efficacy and Safety of AZD0292 in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization
Data & Insights
Has run more than one trial at 338 of 721 partner sites.
Specializations
Respiratory Disease Management
Specializes in investigating treatments for chronic respiratory conditions, with particular focus on bronchiectasis and non-cystic fibrosis bronchiectasis. Conducts research on novel therapeutic approaches including nebulized treatments and antibody-based therapies.
- Bronchiectasis Treatment Development
- Pulmonary Exacerbation Management
- Respiratory Infection Control
Advanced Asthma Care
Focuses on therapeutic interventions for severe asthma and eosinophilic asthma. Investigates innovative treatment approaches including maintenance therapies and biological treatments for patients with inadequate response to conventional treatments.
- Severe Asthma Management
- Eosinophilic Phenotype Treatment
- Long-term Asthma Control
Progressive Lung Disorders
Conducts research in chronic obstructive pulmonary disease (COPD), progressive pulmonary fibrosis, and alpha-1 antitrypsin deficiency. Evaluates innovative treatments including inhalation therapies and targeted molecular interventions.
- COPD Exacerbation Treatment
- Pulmonary Fibrosis Management
- Alpha-1 Antitrypsin Related Conditions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.